JP6087429B2 - 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途 - Google Patents

変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途 Download PDF

Info

Publication number
JP6087429B2
JP6087429B2 JP2015518318A JP2015518318A JP6087429B2 JP 6087429 B2 JP6087429 B2 JP 6087429B2 JP 2015518318 A JP2015518318 A JP 2015518318A JP 2015518318 A JP2015518318 A JP 2015518318A JP 6087429 B2 JP6087429 B2 JP 6087429B2
Authority
JP
Japan
Prior art keywords
tnfri
amino acid
acid sequence
modified
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015518318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525237A5 (enExample
JP2015525237A (ja
Inventor
ソンウク キム
ソンウク キム
スングク パク
スングク パク
ヨンジョン ソン
ヨンジョン ソン
ウンソン キム
ウンソン キム
ヘギョン アン
ヘギョン アン
ジェガプ チョン
ジェガプ チョン
フンギュン イ
フンギュン イ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Biopharma Co Ltd
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Publication of JP2015525237A publication Critical patent/JP2015525237A/ja
Publication of JP2015525237A5 publication Critical patent/JP2015525237A5/ja
Application granted granted Critical
Publication of JP6087429B2 publication Critical patent/JP6087429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015518318A 2012-06-21 2013-02-07 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途 Active JP6087429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120066527 2012-06-21
KR10-2012-0066527 2012-06-21
PCT/KR2013/000983 WO2013191352A1 (en) 2012-06-21 2013-02-07 New uses of modified human tumor necrosis factor receptor-1 polypeptide

Publications (3)

Publication Number Publication Date
JP2015525237A JP2015525237A (ja) 2015-09-03
JP2015525237A5 JP2015525237A5 (enExample) 2016-04-28
JP6087429B2 true JP6087429B2 (ja) 2017-03-01

Family

ID=49768924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518318A Active JP6087429B2 (ja) 2012-06-21 2013-02-07 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途

Country Status (6)

Country Link
US (1) US9580490B2 (enExample)
JP (1) JP6087429B2 (enExample)
KR (1) KR101514238B1 (enExample)
CN (1) CN104394881B (enExample)
BR (1) BR112014031923B1 (enExample)
WO (1) WO2013191352A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6884755B2 (ja) 2015-05-01 2021-06-09 オーエヌエル セラピューティクス，インコーポレーテッド ペプチド組成物および使用方法
WO2017221128A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Methods of treating dry eye disease using tnf alpha antagonists
US20240059768A1 (en) * 2021-01-14 2024-02-22 Hanall Biopharma Co., Ltd. A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizer
KR20230131213A (ko) * 2021-01-14 2023-09-12 한올바이오파마주식회사 탄파너셉트 안과용 조성물을 이용한 안구건조증의 치료

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6379666B1 (en) 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US6204270B1 (en) 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
PL218992B1 (pl) 2002-07-19 2015-02-27 Abbott Biotech Ltd Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ
US20090098136A1 (en) * 2007-10-15 2009-04-16 Alcon Research, Ltd. Use of tnf receptor antagonists for treating dry eye
CN101591388A (zh) * 2008-05-30 2009-12-02 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
EP2492281B1 (en) * 2009-10-19 2018-04-11 HanAll Biopharma Co., Ltd. Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
KR101273893B1 (ko) 2010-09-13 2013-06-14 한올바이오파마주식회사 변형된 인간 종양 괴사 인자 수용체-1 폴리펩티드 또는 그의 절편 및 그의 제조방법
CN103370334B (zh) * 2010-12-23 2016-06-22 韩诺生物制药株式会社 修饰的人肿瘤坏死因子受体-i多肽或其片段及其制备方法

Also Published As

Publication number Publication date
BR112014031923B1 (pt) 2022-02-08
WO2013191352A1 (en) 2013-12-27
BR112014031923A2 (pt) 2017-11-28
US20150119338A1 (en) 2015-04-30
KR20130143484A (ko) 2013-12-31
US9580490B2 (en) 2017-02-28
CN104394881A (zh) 2015-03-04
JP2015525237A (ja) 2015-09-03
CN104394881B (zh) 2016-10-26
KR101514238B1 (ko) 2015-04-28

Similar Documents

Publication Publication Date Title
AU2012326080B2 (en) Etanercept formulations stabilized with meglumine
EP2460881B1 (en) Proteoglycan degrading mutants for treatment of CNS
CA2858962C (en) Compositions of human tear lipocalin muteins and methods of use thereof
US6838429B2 (en) Atopic dermatitis treatment method
JP6087429B2 (ja) 変形されたヒト腫瘍壊死因子受容体−１ポリペプチドの新規用途
US20210113658A1 (en) Coversin for the treatment of cicatrising eye inflammatory disorders
AU2428195A (en) Chondroitinases i and ii, methods of preparation, and use thereof
KR102653532B1 (ko) 수퍼옥시드 디스뮤타제 및 이의 건성안의 예방 또는 치료용 용도
US20120082644A1 (en) Cytokines and neuroantigens for treatment of immune disorders
AU673543B2 (en) Method of inhibiting cell proliferation using apolipoprotein E
KR20110056394A (ko) 폐 질환 치료용 아디포넥틴
JP3030386B2 (ja) 抗ガン剤
JP7742649B2 (ja) ドライアイ疾患のためのｔｓｇ６ポリペプチドフラグメント
CA3202364A1 (en) Dsg2 compositions and methods for the treatment of covid-19
JP2023536229A (ja) Ｎｇｆバリアント、産生、組成物、及び治療的使用
AU2007226130B2 (en) Use of caspases for the preparation of medicaments
KR102646717B1 (ko) 세포 침투성 펩타이드와 fkbp12를 포함하는 융합 단백질 및 이의 용도
EP4426430A1 (en) Dsg2 compositions and methods
CN116966272A (zh) 一种sgp130蛋白在制备治疗角膜炎症及角膜炎适应症产品中的应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160308

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170201

R150 Certificate of patent or registration of utility model

Ref document number: 6087429

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250